Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2017 | 06-2017 | 03-2017 | 12-2016 | 09-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -22,514 | -14,280 | -5,351 | -26,671 | -19,719 |
| Depreciation Amortization | -21 | 22 | 8 | 154 | 149 |
| Accounts payable and accrued liabilities | 185 | 202 | 197 | -109 | -73 |
| Other Working Capital | -298 | -384 | -392 | 290 | -487 |
| Other Operating Activity | 9,088 | 6,346 | 3,335 | 2,983 | 2,179 |
| Operating Cash Flow | $-13,560 | $-8,094 | $-2,203 | $-23,353 | $-17,951 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -72,626 | -722 | -3,224 | 27,170 | 17,352 |
| PPE Investments | N/A | N/A | N/A | -42 | -42 |
| Investing Cash Flow | $-72,626 | $-722 | $-3,224 | $27,128 | $17,310 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -2,327 | -1,534 | -759 | -986 | -244 |
| Common Stock Issued | 101,027 | 9,364 | 9,364 | N/A | N/A |
| Financing Cash Flow | $98,700 | $7,830 | $8,605 | $-986 | $-244 |
| Beginning Cash Position | 10,495 | 10,495 | 10,495 | 7,706 | 7,706 |
| End Cash Position | 23,009 | 9,509 | 13,673 | 10,495 | 6,821 |
| Net Cash Flow | $12,514 | $-986 | $3,178 | $2,789 | $-885 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,560 | -8,094 | -2,203 | -23,353 | -17,951 |
| Capital Expenditure | N/A | N/A | N/A | -42 | -42 |
| Free Cash Flow | -13,560 | -8,094 | -2,203 | -23,395 | -17,993 |